TTrialPathMatch Me to Trials
← Back to trials
RecruitingRespiratory Syncytial Virus Infections+Metapneumovirus

A Study of Investigational RSV/hMPV Combination and Investigational hMPV Vaccines in Younger and Older Adults

Eligible age

18–80 yrs

Accepts

All genders

Locations

2 states

Healthy volunteers

Yes

See if you qualify for this study

Answer a few quick questions about your location and health. Takes about a minute.

Check my eligibility →

About this study

The aim of this study is to evaluate the safety, reactogenicity, and immune response of the different formulations of the investigational RSV/hMPV combination vaccine and investigational hMPV vaccine in younger and older adults.

Sponsor: GlaxoSmithKline

You may qualify if…

  • Participants are eligible to be included in the study only if all of the following criteria apply:
  • Written informed consent obtained from the participant prior to performance of any study-specific procedure.
  • Participants who can and will comply with the requirements of the protocol (e.g., completion of the eDiary, return for follow-up visits, ability to access and utilize a phone or other electronic communications).
  • Body Mass Index (BMI) between 18 kg/m\^2 and 33 kg/m\^2, inclusive.
  • Specific inclusion criteria for OA
  • A male or female between and including, 60 to 80 YOA at the time of the study intervention administration.
  • Healthy participants or medically stable patients as established by medical history and physical examination.
  • Specific inclusion criteria for YA

You may not qualify if…

  • Participants are excluded from participating in the study if any of the following criteria apply:
  • History of any reaction or hypersensitivity likely to be exacerbated by any component of the study intervention(s).
  • Any medical condition that in the judgment of the investigator would make IM injection unsafe.
  • Any confirmed or suspected immunosuppressive or immunodeficient condition resulting from disease (e.g., current malignancy, HIV) or immunosuppressive/cytotoxic therapy (e.g., medication used during cancer chemotherapy, organ transplantation, or to treat autoimmune disorders), based on medical history and physical examination (no laboratory testing required).
  • Acute or unstable chronic pulmonary, cardiovascular, hepatic, or renal functional abnormality, as determined by physical examination and medical history.
  • Documented history of HIV, HBV, HCV infection.
  • History of RSV and /or hMPV-associated illness, diagnosed serologically or microbiologically in the last 12 months.
  • Recurrent history or uncontrolled neurological disorders or seizures, or history of demyelinating conditions (including GBS).

Where it's recruiting

Kansas

Lenexa

Washington

Seattle

Source: ClinicalTrials.gov · NCT07628049 · last updated 2026-08-20

A Study of Investigational RSV/hMPV Combination and Investigational hM · TrialPath